Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

nt with Janssen, total amounts in excess of the annual cap ("Excess Amounts") plus interest may not exceed $225 million.

The Company has recognized the Excess Amounts as a reduction to operating expenses in the current year as the Company's repayment of the Excess Amounts to Janssen is contingent and would become payable only after the third profitable calendar quarter for the product under the collaboration. Further, the Excess Amounts shall be reimbursable only from the Company's share of future full calendar quarter pre-tax profits (if any) after the third profitable calendar quarter for the product under the collaboration.

For the calendar year ended December 31, 2012, the Company's total share of collaboration expenses under the Agreement was $68.1 million. As of December 31, 2012, total Excess Amounts totaled $18.1 million, of which during the quarter ended December 31, 2012, $17.3 million was recorded as a reduction to research and development expense and $0.8 million was recorded as a reduction to general and administrative expense.

GAAP operating expenses were $40.6 million for the six months ended December 31, 2012, compared to $30.6 million for the six months ended December 31, 2011. Included in operating expenses for the six months ended December 31, 2012 is the $18.1 million reduction to operating expenses for Excess Amounts.

GAAP operating expenses were $16.7 million for the quarter ended December 31, 2012, compared to $16.0 million for the quarter ended December 31, 2011 and $23.9 million for the quarter ended September 30, 2012. Included in operating expenses for the quarter ended December 31, 2012 is the $18.1 million reduction to operating expenses for the Excess Amounts.

At December 31, 2012, the Company had cash, cash equivalents and marketable securities of $317.1 million, compared with $203.6 million at June 30, 2012. In addition, as of December 31, 2012, the Company had $26.6 million receivable from Jansse
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , October 30, 2014 ... Holdings Inc. (NYSE MKT: ONVO), Medivation Inc. (NASDAQ: ... ), Synthetic Biologics Inc. (NYSE MKT: SYN), and Ironwood ... companies can be accessed at: http://investor-edge.com/register . ... ended at 4,549.23, down 0.33%, the Dow Jones Industrial ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 ... collaboration provider, offers Office 365 end users the ... a complete phone system by adding voice enablement ... (O365) includes Lync Online, a communication tool that ... calls. With hosted voice, O365 becomes a comprehensive ...
(Date:10/30/2014)... Erlanger, Kentucky (PRWEB) October 30, 2014 Avure ... of the 525L, the newest member of its fleet of ... to be reaching an anniversary as we return to PackExpo ... a year ago in Las Vegas,” said Jeff Williams, CEO ... extremely well, and we’re pleased to be meeting the challenges ...
(Date:10/30/2014)... of the key challenges in the development of quantum ... , In a paper published today (28 October) in ... show how to make a new type of flexibly ... such as high-precision sensors and specialised superfast computers, often ... the methods for trapping these tiny particles are hugely ...
Breaking Biology Technology:Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 4Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 5SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 2SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 3In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3
... , , , SUNNYVALE, ... leader in the field of radiosurgery, announced today that its management is scheduled ... City on Thursday, September 10, 2009 at 11:00 a.m. ET (8:00 a.m. PT). ... available online from the investor relations page of the Company,s Web site at ...
... ... its national print advertising campaign for Cobroxin, the first clinically proven, over-the-counter treatment for ... will run in Arthritis Today, Prevention, Health, Star, Woman,s World, Soap Opera, and Self ... (Vocus) ...
... , CAMBRIDGE, Mass., Sept. 3 Idenix ... management will present a corporate overview at the upcoming Thomas ... at 10:55 a.m. ET at the Four Seasons Hotel in ... Conference on Monday, September( )14, 2009 at 3:55 p.m. ET ...
Cached Biology Technology:Accuray Incorporated to Present at Robert Baird 2009 Healthcare Conference 2Nutra Pharmaceutical's U.S. distributor, XenaCare Holdings Announces National Print Advertising Campaign for Cobroxin, a Treatment for Moderate to Severe (Stage 2) Pain 2
(Date:10/29/2014)... research presented at the Society for Integrative Oncology ... for the first time that it is possible ... readily available nutritional supplement, AHCC. ... Smith, Pharm.D., associate professor in the Department of ... of Texas Health Science Center at Houston (UTHealth) ...
(Date:10/29/2014)... overwhelming number of chemicals from household and industrial products ... our bodies. But for most of them, scientists have ... they,ve taken the first step toward doing that by ... Their new method is published in the ACS journal ... Wambaugh and colleagues note that the risks to human ...
(Date:10/29/2014)... in German . ... and Peter Schlögelhofer at the Max F. Perutz Laboratories ... University of Vienna dived into the process of meiosis ... display an inversion of the standard meiotic phases. The ... Nature Communications . , Meiosis is the two-step ...
Breaking Biology News(10 mins):HPV infections in women eradicated by AHCC, Japanese mushroom extract 2Meiotic cell division 'the other way round' 2
... Molecular Imaging Labs (MI Labs) have succeeded in combining ... of equipment. These techniques are particularly useful for cancer ... microSPECT. SPECT and PET can be performed simultaneously and ... microPET. The new device is known as the VECTor ...
... Properties SA announces the winners of the Reaxys PhD ... PhD or having completed a PhD within the last ... the fields of organic, organometallic and inorganic chemistry. ... launched in January 2010. Submissions consisted of a representative ...
... Navarra, the Polytechnic University of Madrid (CBGP), the University ... Institute of Agricultural Research have managed to sequence the ... olive tree. The study, included in the June issue ... of the genome of a pathogenic bacteria undertaken in ...
Cached Biology News:TU Delft and MI Labs merge PET and SPECT biomedical imaging techniques and increase resolution 2The Reaxys Ph.D. Prize awards innovative research in organic, organometallic and inorganic chemistry 2The Reaxys Ph.D. Prize awards innovative research in organic, organometallic and inorganic chemistry 3Genome of bacteria responsible for tuberculosis of olive tree sequenced 2
...
Fetal Calf Serum Replacement (Bistec) serum...
NEWBORN CALF SERUM AND PLASMA...
... phase reagent for Virus ... & unique water insoluble ... detergents and chaotropes; Engineered ... non-envelop viruses while preserving ...
Biology Products: